Atomo Secures US$410 thousand Order for Pascal Cassettes Amid Growing US Demand for FebriDx.

Atomo Diagnostics Limited (ASX: AT1) has received a US$410,000 (AU$630,000) order from Lumos Diagnostics (ASX: LDX) for its Pascal test cassettes. This marks the first order since Lumos entered a six-year exclusive U.S. distribution agreement with PHASE Scientific for the FebriDx® test. FebriDx, which incorporates Atomo’s patented Pascal cassette, has already achieved 510k FDA clearance and is nearing completion of a CLIA waiver study expected this month.

Lumos projects potential FebriDx sales of up to US$316 million over the contract term, provided CLIA approval is granted and minimum order quantities are met. As the exclusive manufacturer and supplier of Pascal, Atomo anticipates a major increase in U.S. demand. Atomo’s Managing Director John Kelly expressed confidence in supporting Lumos’s scale-up efforts to meet the expected surge in FebriDx demand, reinforcing Atomo’s position in the global rapid diagnostics market.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com